SGLT2 Inhibitor for Cardiac Protection in a Patient With Osimertinib-Responsive Advanced EGFR-Positive Lung Cancer Authors: Aditya V Belamkar, Marwan Mounayar, Suparna C Clasen Published: 2024 ABSTRACT AbstractAn 85-year-old man with recently diagnosed metastatic EGFR+ lung adenocarcinoma treated with osimertinib presented after 1 month of therapy in decompensated congestive heart failure along with atrial fibrillation, prolonged QTc and acute kidney injury. Osimertinib was held. His hemodynamic status was optimized, and he was started on cardioprotective medications (losartan and metoprolol succinate), and LVEF recovered. However, after reintroducing osimertinib, LVEF reduced, indicating possible osimertinib-induced cardiomyopathy. An SGLT2 inhibitor was added for cardioprotection before another rechallenge of osimertinib. SGLT2 inhibitors are a powerful tool for heart failure and may have a potential secondary benefit in ameliorating cardiotoxic processes. Although their use in osimertinib-induced cardiomyopathy has not been well-established, current heart failure guidelines and emerging research support its use in this setting. This case and the accompanying literature review highlight the novel use of SGLT2 inhibitors coupled with regular clinical and imaging monitoring, as a compelling intervention for osimertinib-induced cardiomyopathy.Key Words: cardiomyopathy, heart failure, osimertinib, SGLT2 inhibitor Visual Summary. The Course of Events Is Charted From the Onset of Osimertinib Therapy in February 2022 Through August 2024 History of Presentation In this report, we discuss an 85-year-old man with epidermal growth factor receptor (EGFR) positive non–small cell lung adenocarcinoma (NSCLC) treated with osimertinib 80 mg orally. Osimertinib has been shown to significantly prolong disease-free survival in patients with stage IB to IIIA EGFR sequence variant NSCLC compared with placebo in the ADAURA (Adjuvant Osimertinib for Resected EGFR-mutated Non-small Cell Lung Cancer) trial1 and is considered an ideal therapeutic option for this patient. Within 1 month of treatment, the patient was hospitalized for progressive respiratory distress and volume overload (Figures 1A and 1B) and was in atrial fibrillation (AF) with rapid ventricular response and heart failure (HF) exacerbation. He presented with a B-type natriuretic peptide of 666 pg/mL (reference value <100 pg/mL) and, on point-of-care ultrasound, left ventricular ejection fraction (LVEF) was mildly reduced on visual estimate. High-sensitivity troponins remained normal. He was volume-optimized with diuretic agents, and his AF was aggressively managed with metoprolol succinate 50 mg daily, dronedarone 400 mg twice daily, and apixaban 5 mg twice daily. At discharge, the patient returned to normal sinus rhythm, and a subsequent echocardiogram showed an LVEF of 60% with normalized filling pressures. Given preserved LVEF, his osimertinib was restarted after collaborative decision-making between the medical oncologist and cardiologist. However, within 3 months of continued therapy, the patient demonstrated an LVEF of 46% on echocardiography (Videos 1A and 1B), and osimertinib was held. Arrhythmia monitoring showed normal sinus rhythm, and it was felt that LVEF decline was not secondary to occult AF burden. Three subsequent echocardiograms showed recovered and normalized LVEF, and osimertinib was restarted with losartan 25 mg for cardioprotection. Follow-up echocardiograms demonstrated a stabilized LVEF of 60%. With ongoing osimertinib usage, 11 months after his previous reduction in LVEF, the patient experienced an asymptomatic decline in LVEF to 45%, and osimertinib was held once again. Take-Home Messages •Osimertinib causes dose-dependent, reversible cardiotoxicity in patients who can present with symptomatic or asymptomatic HF, reduced ejection fraction, arrhythmias, and prolonged QTc. Osimertinib causes dose-dependent, reversible cardiotoxicity in patients who can present with symptomatic or asymptomatic HF, reduced ejection fraction, arrhythmias, and prolonged QTc. •SGLT2 inhibitors for osimertinib-induced cardiomyopathy is a novel use of this class of medications that poses an exciting potential for cardioprotection in the cardio-oncology population. SGLT2 inhibitors for osimertinib-induced cardiomyopathy is a novel use of this class of medications that poses an exciting potential for cardioprotection in the cardio-oncology population. Chest Radiograph and Chest Computed Tomography With Intravenous Contrast 1 Month After Starting Osimertinib (A) Chest radiograph in March 2022, 1 month after starting osimertinib, showed development of right basilar airspace disease and right pleural effusion with stable left upper lobe pulmonary mass. (B) Chest computed tomography with intravenous contrast in March 2022, 1 month after starting osimertinib, showed stable left upper lobe pulmonary mass, new development of a small pericardial effusion, moderate-sized right pleural effusion, and a small left pleural effusion. Past Medical History The patient was previously diagnosed with paroxysmal AF, transient ischemic attack, and hypothyroidism. He maintains an active lifestyle and is a never-smoker. His NSLC was initially diagnosed when he presented for evaluation of a posterior chest wall injury following a mechanical fall while working outdoors. Initial chest radiograph noted a concerning lung opacity. Follow-up computed tomography scan revealed a 2.5 × 3.0 × 2.7 cm mass in the left upper lobe with enlarged mediastinal and hilar lymph nodes without pleural effusion or another metastatic disease. Computed tomography–guided biopsy with subsequent molecular panel revealed a diagnosis of adenocarcinoma positive for EGFR sequence variant L858R on exon 21 and negative for BRAF and KRAS mutations. Given staging and patient focus on quality-of-life measures, osimertinib and denosumab were recommended. Differential Diagnosis The differential diagnosis for acute decompensation included atrial fibrillation, ischemia, valvular disease, and uncontrolled hypertension. An electrocardiogram showed AF without ischemic changes, and high-sensitivity troponins were unremarkable on admission. His local electrophysiologist intermittingly monitored AF burden, but he maintained a normal sinus rhythm after adding dronedarone. With each HF exacerbation, the LVEF did not drop below 35%, and it was felt that the benefit of maintaining sinus rhythm outweighed the risk of worsening HF. Clinical history and serial imaging ruled out ischemic or valvular causes for his cardiomyopathy. The patient has remained normotensive. Investigations Serial echocardiography and electrocardiograms were performed on the patient. Due to the lower pretest probability of ischemic cardiomyopathy, additional ischemic evaluation was deferred. Management A discussion was had on continuing osimertinib vs switching to erlotinib, which has fewer reported cases of cardiomyopathy. Given the superior central nervous system penetration of osimertinib, cardiac function was closely monitored. Traditional cardioprotective agents (metoprolol succinate, losartan) at maximally tolerated doses were insufficient because the patient continued to have LVEF decline. Our patient had marginal blood pressure room for adding sacubitril-valsartan and spironolactone. Atrial fibrillation was well-controlled and was not thought to be the underlying cause. The patient had mildly reduced renal function, with fluctuations correlating with HF exacerbations. A literature review yielded several case reports of patients with reduced LVEF and prolonged QT intervals on osimertinib, similar to our patient’s presentation (Table 1). SGLT2 inhibitors were considered for guideline-directed medical management for heart failure and renal protection, and given the potential attenuation of cardiotoxic processes, they were the ideal choice for our patient. He was restarted on osimertinib for a final challenge with aggressive protection with empagliflozin 10 mg, losartan 12.5 mg titrated back from 25 mg because of orthostatic hypotension, and metoprolol succinate 50 mg with close echocardiography with strain every 3 months. Table 1Cases of Osimertinib-Induced CardiotoxicityFirst Author, YearAge (y), SexCardiovascular ComorbiditiesClinical Presentation and Diagnostic TestingTime After InitiationNT-proBNPCK-MBTroponinLVEF, %InterventionOutcomesPiper-Vallillo et al,11 202067, FHypertension, hypothyroidism, pulmonary embolismHFrEF with new-onset LBBB, no significant QTc prolongation7 mo1,104 pg/mL42Lisinopril later replaced by sacubitril-valsartan; metoprolol later discontinued, discontinued osimertinibLVEF found to be stable 4 wks after resuming erlotinib, asymptomatic for HFWatanabe et al,12 201778, FUnknownMild exertional dyspnea and accompanying decreasing oxygen saturation, imaging demonstrated bilateral pleural effusions and pulmonary congestion as well as left atrial dilatation3 wks224 pg/mLNot elevatedDiuretic, discontinued osimertinibRecovered within 5 d of cessation of treatment and diuretic administration, did not require continued diureticOkuzumi et al,13 202291, MHypertension, chronic kidney diseaseSymptomatic HFrEF, echocardiography showed diffuse hypokinesis with reduced EF6 wks321.1 pg/mL48IV furosemide 40 mg daily for 4 d, discontinued osimertinibLVEF, BNP, and symptoms normalized 1 wk after treatment discontinuationMedepalli et al,14 202270, FFormer smoker, mild mitral and tricuspid regurgitationAnorexia, nausea, decreased oral intake, and weight loss, prolonged QTc interval, mild to moderate mitral regurgitation, mild aortic regurgitation, moderate to severe tricuspid regurgitation, and mild pulmonary hypertension6 mo680 pg/mL0.062 ng/mL40-45Electrolyte replacement focused on optimizing potassium, continued osimertinibQTc normalized after 72 hReale et al,15 201870, MFormer smoker, hypertensionHFrEF3 mo45Ramipril 2.5 mg, bisoprolol 1.25 mg, discontinued osimertinibEF improved after 3 wks of treatment withdrawal, but symptoms and overall clinical condition continued to worsen despite management and patient passed73, FIntermittent left bundle branch block, hypertensionAsymptomatic LVEF reduction and worsening mitral valve insufficiency14 mo58Bisoprolol 1.25 mg increased to 3.75 mg after the second reduction in LVEF, discontinued osimertinib with each reductionRecovered EF after 3 incidences with beta-blocker therapy and therapy suspension; however, restarting osimertinib lead to similar reductions47, FNoneHFrEF17 mo51Bisoprolol 5 mg, perindopril 5 mg, osimertinib suspendedSystolic function recovered and osimertinib was restarted; no further reductions were noted71, FNoneLeft-sided dilatation and associated dyspnea11 mo45Bisoprolol 2.5 mg, furosemide 12.5 mg, perindopril 2.5 mg, osimertinib suspendedPartial recovery of systolic function with regression of dyspnea was noted and osimertinib was resumed 15 d later without complication80, FNoneAsymptomatic LVEF reduction and LA volume and LV mass increase11 mo43Enalapril titrated from 2.5-5 mg, osimertinib suspendedLVEF improved and left-sided volumes stabilized, osimertinib was restarted but LVEF reduced twice more before being discontinuedPatel et al,16 202084, FCoronary artery disease s/p coronary artery bypass graft, prior ischemic strokePulmonary edema, decreased LVEF with severe global LV hypokinesis4 wks22,579 pg/mL29-31 ng/L20Furosemide, losartan, bisoprolol, osimertinib discontinuedEuvolemic after 4 wks with mildly improved EF, initiated on erlotinib71, MAtrial fibrillation, hypertension, hyperlipidemiaAcute-onset dyspnea and peripheral and pulmonary edema, reduction in LVEF with global hypokinesis and moderate LV enlargement12 d2,138 pg/mL843 ng/L39Diuresis, lisinopril, and metoprolol, osimertinib discontinuedReturned to baseline clinical status and was rechallenged with osimertinib because of confounding cardiac history, has not had further exacerbation72, FNoneProgressive dyspnea and hypoxia, pulmonary edema and reduced LVEF1 mo7,306 pg/mL39ACEI, beta-blocker, diuretic started, osimertinib discontinuedNormalization of EF 2 mo later, switched to erlotinibKunimasa et al,17 202078, FHypertension, h/o thoracic aortic aneurysmDyspnea, found to have prolonged QTc, severely reduced LVEF with moderate to severe mitral regurgitation3 mo18,890 pg/mL0.416 ng/mL28Furosemide 40 mg, spironolactone 50 mg, tolvaptan 7.5 mg, carvedilol 5 mg, and candesartan 2 mg initiated, osimertinib discontinuedLVEF remained reduced 3 mo after discontinuation but progressively improved after 9 mo72, FHypertensionFatigue, severe mitral regurgitation with mitral valve prolapse3 mo74Furosemide 20 mg, osimertinib discontinuedSymptoms improved after 1 mo but mitral regurgitation persisted but did not worsen, switched to gefitinib68, MNoneFatigue and lower extremity pitting edema, QTc prolongation, severe hyponatremia (120 mEq/L), severe tricuspid regurgitation, and mild pulmonary hypertension3 moTolvaptan 3.75 mg, furosemide 40 mg, osimertinib suspendedFatigue and edema improved after 1 mo, severe tricuspid regurgitation persisted and osimertinib was restarted at lower dose (40 mg)64, FModerate mitral regurgitationFatigue and lower extremity pitting edema, elevated NT-proBNP9 mo227.9 pg/mL50Furosemide 20 mg, spironolactone 25 mg, osimertinib suspendedSymptoms resolved, LVEF improved, and NT-proBNP reduced after 1 mo, osimertinib was restarted without complication52, FObesityAsymptomatic reduction in LVEF, normal QTc2 wks36 pg/mL<0.01 ng/mL41Candesartan 4 mg, osimertinib discontinuedLVEF recovered and patient was treated with afatinib71, FHypertension, diabetes mellitusSudden dyspnea and chest pain found to have QS pattern in V1-4, and anteroseptal hypokinesis2 mo7.2 ng/mL2.945 ng/mL42Percutaneous coronary intervention of the left anterior descending arterySwitched to erlotinibIkebe et al,18 202184, FFormer smoker, hypertensionDyspnea and bilateral lower extremity edema, cardiomegaly, bilateral pleural effusion, QTc prolongation and poor R progression, dilated and diffusely hypocontractile LV2 mo7,469 pg/mLNormalNormal35IV furosemide transitioned to oral azosemide and spironolactone; oral enalapril and bisoprolol; osimertinib discontinuedQTc normalized and LVEF improved, passed away from cancer progression 15 mo after therapy discontinuationFukuo et al,19 202274, FComplete left bundle branch blockQT prolongation1 mo1,175 pg/mL58 pg/mL31Telmisartan 20 mg converted to enalapril 1.25 mg, carvedilol converted to bisoprolol 1.25 mg, ivabradine 5.0 mg initiated to modulate heart rate, osimertinib suspendedImproved LVEF and reduced BNP 1 mo after, osimertinib restarted at 40 mg without recurrenceBardaro and Stirpe,20 202279, FHypertension, type 2 diabetesAcute respiratory failure and HF with QT prolongationDiuretic agents, beta-blocker, oxygen, discontinued osimertinibRequired increased therapy because of worsening HF but maintained stable clinical improvement afterwardsRuiz-Briones et al,21 2023FLeft bundle branch block, dyslipidemia, hypertensionSevere HFrEFSuspended osimertinibResumed osimertinib after stabilization of HF without complication, developed atrial fibrillation during hospital admission for HFIto et al,22 202073, FNoneDyspnea on exertion and increased pleural effusion, elevated BNP and reduced EF6 mo19Diuretic, beta-blocker treatment, discontinued osimertinibImprovement in EF and HF symptomsKobat et al,23 202372, MFormer smoker, type 2 diabetes, hypertension, hypercholesterolemiaQTc prolongation and atrial fibrillation with reduced LVEF15 mo30Dabigatran, bisoprolol, digoxin, ramipril, and spironolactone were startedOsimertinib was continued without complication after optimizing cardiac management, patient passed because of cancer progressionZhang et al,24 202262, FNoneWeakness and lower extremity edema, pleural and pericardial effusions, severe LV hypokinesis6 mo6,830 ng/L36Furosemide, spironolactone, bisoprolol, valsartan, discontinued osimertinibLVEF improved after 4 wks and aumolertinib was administeredFukuda et al,25 202273, FNoneProgressive shortness of breath, fatigue, and edema, increased LV dimension, right bundle branch block, and prolonged QTc1 mo1,002.1 pg/mL58Spironolactone 25 mg, bisoprolol 1.25 mg, suspended osimertinibLV motion improved to almost normal kinesis and electrocardiogram changes normalized after 35 d, restarted osimertinib at 40 mg but cardiac complications reappeared 63 d later and treatment was stopped with subsequently improved cardiac functionTeran Brage et al,26 202262, FNoneAcute myocarditis with severe LV dysfunction and cardiogenic shock 24 h after receiving a third dose of the COVID-19 vaccine and the influenza vaccine2 mo8.069 pg/mL12.487,6 pg/mLSeverely depressedDobutamine and noradrenaline, glucocorticoids and immunoglobulins, ventricular assist device (Impella) implantation, antibiotics for central catheter infectionDischarged from hospital, unknown outcomesShinomiya et al,27 202076, FNoneFever and progressive dyspnea, diagnostic endomyocardial biopsy indicated osimertinib-induced cardiomyopathy4 mo1,394 pg/mL40.9 pg/mL17Furosemide, carvedilol, enalapril, discontinued osimertinibSymptoms, cardiac function, and condition improved 3 wks following treatmentTanaka et al,28 202370s, MSmokerBilateral pleural effusion and expansion of the inferior vena cava with cardiac enlargement6 mo2,130.1 pg/mL39 mg/dL20Diuretic and beta-blocker, discontinued osimertinibGradual improvement in cardiac functionPatel et al,29 202363, MFormer tobacco use, hypertension, type 2 diabetes mellitusLarge pericardial, cardiac MR imaging findings showed focal late gadolinium enhancement and myocardial edema4 wks666 pg/mL2.2 ug/L30-35Initiated on empagliflozin, spironolactone, and metoprolol, discontinued osimertinibNormalization of LVEF and trace pericardial effusion after 3 moSaito et al,30 202366, FNoneSyncope, ECG showed polymorphic nonsustained ventricular tachycardia10 d4.4 ng/mL0.03 ng/mLSwitched to erlotinibOsimertinib was trialed at 40 mg every other day before progressing to daily administration without further cardiac eventsXu et al,31 202462, MSmoking history, type 2 diabetes mellitusRespiratory distress, fever, cough, and expectoration, CMR showing LV enlargement, thinning and fibrosis of the lateral myocardial wall without perfusion defects18 mo, 24 moNo value, 7,193 pg/mLWithin normal limits36, 35Torsemide, spironolactone, metoprolol, and daglitazone improved HF symptoms, osimertinib was discontinuedFollow-up imaging showed no recurrence of primary tumor so osimertinib was not restarted, EF improved with medicationBNP = B-type natriuretic peptide; CMR = cardiovascular magnetic resonance; ECG = electrocardiogram; EF = ejection fraction; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LA = left atrial; LBBB = left bundle branch block; LV = left ventricular; LVEF = left ventricular ejection fraction; MR = magnetic resonance; NT-proBNP = N-terminal pro–B-type natriuretic peptide. Cases of Osimertinib-Induced Cardiotoxicity BNP = B-type natriuretic peptide; CMR = cardiovascular magnetic resonance; ECG = electrocardiogram; EF = ejection fraction; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; IV = intravenous; LA = left atrial; LBBB = left bundle branch block; LV = left ventricular; LVEF = left ventricular ejection fraction; MR = magnetic resonance; NT-proBNP = N-terminal pro–B-type natriuretic peptide. Outcome and Follow-Up At 3-month follow-up, the patient tolerated his medications without reduction in LVEF, QTc prolongation, or other signs of HF. His AF continued to be well-controlled on the existing medication regimen. At 12-month follow-up, the patient remained clinically stable and asymptomatic, having had stable electrocardiographic and echocardiographic examinations (Videos 2A and 2B). Discussion NSCLC management has been dramatically advanced with the identification of targeted therapies. The most recent is osimertinib (Tagrisso), which was first approved by the U.S. Food and Drug Administration in 2018 for EGFR exon 19 deletions or exon 21 L858R sequence variant NSCLC. Although it has many beneficial therapeutic effects, there are emerging reports of its cardiotoxicity, specifically HF exacerbation, arrhythmias, and QT prolongation (Table 1). SGLT2 Inhibitors SGLT2 inhibitors (ie, empagliflozin, dapagliflozin) inhibit the sodium-glucose cotransporter in the proximal convoluted tubules and are used in the management of type 2 diabetes mellitus, HF, and chronic kidney disease. These therapies are known to improve outcomes and reduce mortality in HF patients regardless of comorbidity status or LVEF, carrying a Class IIa recommendation in similar patients per current guidelines. In anthracycline- and trastuzumab-induced cardiotoxicity, SGLT2 inhibitor use has demonstrated anti-inflammatory properties, reducing inflammatory markers (interleukin 6, C-reactive protein, tumor necrosis factor-α, and monocyte chemoattractant protein-1) in animal models.2 Trastuzumab has dose-independent, reversible cardiotoxic properties by blocking EGFR2 on cardiac myocytes. Empagliflozin may attenuate this by suppressing a DNA damage ferroptosis-mediated mechanism in animal models.3 Conversely, anthracyclines (ie, doxorubicin) typically have dose-dependent, irreversible cardiotoxic properties through a complex interplay of mitochondrial damage and free radical generation. SGLT2 inhibitors may lower the rate of cardiac events and prevent left ventricular dysfunction in cancer patients treated with anthracyclines.4,5 Osimertinib Osimertinib is an effective oral treatment for NSCLC.1 Ewer et al6 performed a post hoc analysis of cardiac data from the FLAURA (First-Line Osimertinib in Advanced Non-Small Cell Lung Cancer) and AURA3 (A trial of osimertinib for non small cell lung cancer) studies and did not find a causal relationship between osimertinib and HF. They found a decrease in LVEF of over 10% in 3.9% of all patients, with most of the events being asymptomatic and resolving without further treatment or therapy discontinuation.6 Although the pharmacokinetic and pharmacodynamic analysis found no relationship between osimertinib exposure and LVEF reduction, the authors note that LVEF decreases were observed in patients with cardiac risk factors before osimertinib treatment; therefore, cardiac monitoring is advised.6 Osimertinib has been strongly associated with increased odds of QT prolongation, arrhythmias, and HF compared with other targeted treatments for NSCLC in a large-scale study of 98,765 reported adverse reactions.7 Another retrospective review of the U.S. Food and Drug Administration Adverse Events Reporting System found the odds for HF, AF, QT prolongation, myocardial infarction, and pericardial effusion were significantly increased with osimertinib use compared with all other drugs in the system and other EGFR tyrosine kinase inhibitors.8 A study of 58 patients noted reduced LVEF that improved with discontinuation, dose reduction, or switching tyrosine kinase inhibitors in most patients.9 This data has been supported by several case studies (Table 1). Osimertinib appears to follow a dose-dependent, reversible model. Trastuzumab has been well-established to have cardiotoxic adverse events, and the mechanism of osimertinib is theorized to share similarities. A study conducted in isolated hearts of guinea pigs found acute exposure to osimertinib blocked hERG, Nav1.5, and L-type Ca channels in a concentration-dependent mechanism, prolonging the QT interval, PR interval, QRS interval, left atrium, left ventricle, and atrioventricular conduction time.10 Further research is necessary to understand the development of osimertinib-related cardiotoxicity and to determine the most efficacious combination of cardioprotective agents for these cases of cardiotoxicity. In summary, we recommend that osimertinib-induced cardiotoxicity be managed by first discontinuing osimertinib and then aggressive guideline-directed HF management, with a focus on starting an SGLT2 inhibitor. Close monitoring of clinical signs of HF and serial echocardiograms may be warranted in higher-risk patients with the reintroduction of osimertinib. Conclusions This case highlights the critical need for proactive management mitigating cardiovascular risks associated with anticancer therapies. Given the oncologic impact of osimertinib discontinuation, it is imperative to develop meticulous protocols to monitor cardiovascular complications while allowing for appropriate and necessary oncologic therapies. Permissive cardiotoxicity suggests that specific therapies may indirectly exacerbate cardiovascular risks, necessitating a nuanced approach to intervention balancing the needs for oncologic outcomes with minimizing cardiovascular adverse effects. Adding SGLT2 to traditional guideline-directed medical therapy and regular clinical and imaging monitoring offers a compelling intervention in controlling osimertinib-induced cardiomyopathy. This dual approach holds promise in managing acute cardiovascular impacts and ensuring the sustained effectiveness of this essential therapy. Funding Support and Author Disclosures Dr Clasen is supported in part by National Institutes of Health-NCI Grant 2L30CA264679-02; has performed a personal consulting or advisory role for Sumitomo Pharma Oncology; and has family member employment and stock/other ownership interests in Eli Lilly and Company. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental videos, please see the online version of this paper. Appendix Video 1a Apical 2 Chamber (A2C) View of Transthoracic Echocardiogram (TTE) in April 2023 TTE showed LVEF reduced to 45%, average LV cavity size and wall thickness, stage 1 diastolic dysfunction, no regional wall motion abnormalities, grossly normal right ventricle and left atrium, moderate right atrial dilatation, and moderate mitral valve regurgitation. Video 1b Apical 4-Chamber (A4C) View of TTE in April 2023 Video 2a A2C View of TTE in July 2024 TTE showed LVEF recovered to 62%, normal LV cavity size, mild concentric LV hypertrophy, stage 1 diastolic dysfunction, no regional wall motion abnormalities, mild right atrial and ventricular dilatation, moderate left atrial dilatation, and moderate mitral valve regurgitation. Video 2b A4C View of TTE in July 2024. References Associated Data Supplementary Materials Video 1a Apical 2 Chamber (A2C) View of Transthoracic Echocardiogram (TTE) in April 2023 TTE showed LVEF reduced to 45%, average LV cavity size and wall thickness, stage 1 diastolic dysfunction, no regional wall motion abnormalities, grossly normal right ventricle and left atrium, moderate right atrial dilatation, and moderate mitral valve regurgitation. Video 1b Apical 4-Chamber (A4C) View of TTE in April 2023 Video 2a A2C View of TTE in July 2024 TTE showed LVEF recovered to 62%, normal LV cavity size, mild concentric LV hypertrophy, stage 1 diastolic dysfunction, no regional wall motion abnormalities, mild right atrial and ventricular dilatation, moderate left atrial dilatation, and moderate mitral valve regurgitation. Video 2b A4C View of TTE in July 2024.